22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The coronavirus has disrupted the economy and business activity, making it difficult or challenging ...
Read More >
Effective September 29, 2019, Illinois has amended the Illinois Equal Pay Act of 2003 to prohibit em...
Read More >
New York Governor Andrew Cuomo recently signed legislation amending state law to explicitly prohibit...
Read More >
The EAT upheld an Employment Tribunal (ET) decision that the dismissal of a Probation Service Office...
Read More >
In a recently issued procedural notice, the Small Business Association (“SBA”) addressed a lingeri...
Read More >
Oregon’s active 2019 legislative session has prompted the need for several policy and handbook upda...
Read More >